PFAS & Microplastics: How can you operationalize the EPAs new Contaminant Candidate List (CCL)?

In April 2026, EPA released the draft Sixth Contaminant Candidate List (CCL 6). The Contaminant Candidate List (CCL) is an Environmental Protection Agency (EPA) program established under the Safe Drinking Water Act to identify unregulated contaminants that are known, or anticipated to occur, in public water systems and that may warrant future regulatory consideration. The CCL does not create new requirements; rather, it functions as an upstream prioritization tool that guides EPA’s focus on health effects research, occurrence data collection, analytical method development, future monitoring, and evaluation.

Since its inception, the CCL has evolved through multiple iterations (CCL 1 through CCL 5), becoming progressively more data-rich and structured, reinforcing its role at the front end of the regulatory pipeline. EPA released the draft CCL 6 in April 2026, following the finalization of recent regulatory determinations, reinforcing the CCL’s role at the front end of the regulatory pipeline.

One of the most notable evolutions in CCL 6 is that, for the first time, both PFAS and microplastics appear as group listings, rather than solely individual substances. When the EPA lists an individual contaminant, it is evaluating a specific chemical with a defined measurement approach and a clearer pathway to occurrence assessment and health evaluation. A group listing signals something broader: EPA is prioritizing the work needed to define the category, standardize measurement, and build comparable datasets before any regulatory determination is even possible. That shift is important, but how we interpret it is even more important.

The takeaway that matters is that CCL 6 reflects EPA leaning further into group‑based thinking without implying that all groups are equally ready for regulation. Put simply, parts of the PFAS universe are already operating within a defined regulatory and technical framework, while microplastics remain, at this stage, largely a research and methods problem.

Here’s the practical distinction. For PFAS, the regulatory and technical foundation is already partially built: there are established drinking water standards for a subset of PFAS compounds, widely used analytical methods, and a growing national occurrence data to benchmark risk and compliance planning as well as support decision-making. Microplastics are different. The central questions are still being resolved. The field is still working toward consistent definitions (what counts, by size and particle type), validated analytical methods with robust QA/QC, and health-based benchmarks that anchor interpretation.

Until those anchors exist, the most defensible action is targeted research, method development, and careful planning. Recognizing that distinction is essential to reading the list correctly.

If you operate a public water system, manage industrial compliance, own infrastructure, develop property, or oversee environmental risk, draft CCL 6 is not an immediate new requirement. It is, however, a reliable indicator of where attention will concentrate over the coming years. Expect a more data-driven landscape in which questions arrive before standards; increased expectations for sampling design and QA/QC; more scrutiny on how results are interpreted, and more stakeholder pressure to explain what detections do (and do not) mean. For most organizations, this is less about immediate compliance and more about how you prepare for what comes next.

CCL 6 includes PFAS, disinfection byproducts, pharmaceuticals, and microplastics on the same list, which can create an impression of equivalence. In reality, these categories sit at very different stages of scientific and operational maturity. The implication is straightforward: near-term decisions should not treat every CCL category the same.

For PFAS, many organizations are already in an “action” phase, confirming occurrence, evaluating treatment or source-control options, and aligning with regulatory timelines. At present, the smarter move for microplastics is to build readiness without overcommitting: understand likely sources, track emerging methods, and plan for how results will be interpreted and communicated as the science matures.

A disciplined way to respond is to separate near-term action from long-term readiness. Start by confirming what you already know: what has been sampled, using what methods, with what detection limits and QA/QC? Then decide what the next decision actually is: screening, compliance planning, design, or stakeholder communication, and tailor monitoring accordingly?

For PFAS, that often means refining sampling plans, validating laboratories and methods, and evaluating treatment or source-control pathways that are technically feasible and proportionate to risk. For microplastics, it may mean developing a baseline approach, tracking method validation developments, and setting internal decision points for how findings will be communicated responsibly while benchmarks are still evolving.

If you want a clear way to operationalize CCL 6 without overreacting, focus on three deliverables: a defensible sampling and QA/QC approach, a clear framework for interpreting results, and a phased roadmap that aligns technical actions with regulatory maturity.

This is the difference between reacting to a signal and converting it into decision-ready progress.

Looking ahead, CCL 6 is a useful lens into what is coming: continued expansion of class- and group-based regulatory thinking, increased investment in analytical methods and data defensibility, and more targeted monitoring and iterative evaluation. In other words, over the next few years, you should anticipate more guidance, more pilot efforts, and more requests for defensible data, especially where group-based categories are still being defined. The best preparation is not to guess where regulation will land, but to build decision-ready information: data you trust, documentation you can stand behind, and a plan that can adapt as definitions, methods, and benchmarks tighten.

CCL 6 does not ask us to move faster. It asks us to move smarter. And, in a space where science is still unfolding, both understanding and clarity, applied at the right time, creates the real advantage.